Microbix Biosystems, Inc. (MBX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 4.89%

The company has been able to generate a Return on Equity (avg) of 4.89% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate 12.97% of over the last 5 years

With a fall in Net Sales of -34.79%, the company declared Very Negative results in Jun 25

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 35 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.24

Return on Equity

-1.11%

Price to Book

1.19

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.0%

6 Months

-32.39%

1 Year

-29.41%

2 Years

-35.14%

3 Years

-53.85%

4 Years

-59.32%

5 Years

-17.24%

Microbix Biosystems, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

13.12%

EBIT Growth (5y)

12.97%

EBIT to Interest (avg)

1.52

Debt to EBITDA (avg)

0.46

Net Debt to Equity (avg)

-0.31

Sales to Capital Employed (avg)

0.64

Tax Ratio

8.78%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

11.47%

ROE (avg)

4.89%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.26

EV to EBIT

29.96

EV to EBITDA

13.39

EV to Capital Employed

1.35

EV to Sales

1.42

PEG Ratio

Dividend Yield

ROCE (Latest)

2.38%

ROE (Latest)

-1.11%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -33.96% vs -11.67% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.50",
          "val2": "5.30",
          "chgp": "-33.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "0.60",
          "chgp": "-250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-382.90%",
          "val2": "33.50%",
          "chgp": "-41.64%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 53.94% vs -13.61% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs -100.00% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.40",
          "val2": "16.50",
          "chgp": "53.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.50",
          "val2": "-1.60",
          "chgp": "443.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.80",
          "chgp": "12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "3.10",
          "chgp": "-93.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.50",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.80%",
          "val2": "-165.70%",
          "chgp": "31.95%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

3.50

5.30

-33.96%

Operating Profit (PBDIT) excl Other Income

-0.90

0.60

-250.00%

Interest

0.20

0.30

-33.33%

Exceptional Items

0.00

Consolidate Net Profit

-1.60

0.00

Operating Profit Margin (Excl OI)

-382.90%

33.50%

-41.64%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -33.96% vs -11.67% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'24

Sep'24

Sep'23

Change(%)

Net Sales

25.40

16.50

53.94%

Operating Profit (PBDIT) excl Other Income

5.50

-1.60

443.75%

Interest

0.90

0.80

12.50%

Exceptional Items

0.20

3.10

-93.55%

Consolidate Net Profit

3.50

-0.00

Operating Profit Margin (Excl OI)

153.80%

-165.70%

31.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2024 is 53.94% vs -13.61% in Sep 2023

Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 0.00% vs -100.00% in Sep 2023

All Annual Results

Company CV

About Microbix Biosystems, Inc.

Microbix Biosystems, Inc.

Pharmaceuticals & Biotechnology

Microbix Biosystems Inc is a Canada-based life science company and manufacturer of viral and bacterial antigens and cell, culture-based biological products and technologies. The Company has developed and acquired two technologies: Kinlytic Urokinase and LumiSort. Kinlytic Urokinase is a biologic thrombolytic drug used to treat blood clots. LumiSort is a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest. The Company's catalogue of antigens covers over 30 bacterial and viral pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.

Company Coordinates

Company Details

265 Watline Avenue , MISSISSAUGA ON : L4Z 1P3

Tel: 1 905 3618910

https://microbix.com/

Registrar Details